Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PF-08653944

Phase 3Small molecule

PF-08653944 is one of 46 small molecule programs targeting Obesity. It is currently in Phase 3.

1

Indications

6

Total Trials

5

Active Trials

45

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityActive, not recruiting

ObesityPhase 3

Active, not recruiting

Competition

Competitive Landscape

176 competitors in Obesity

#DrugCompanyPhaseTrials

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Maridebart Cafraglutide

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Cagrisema

Eloralintide

Naltrexone-Bupropion Combination

CCurrax Pharmaceuticals

Belantamab Mafodotin-Blmf

PF-08653944

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Actemra

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Obesity

NCT07508241

Phase 1Not yet recruiting

Obesity

NCT07845513

Q1 2028

Phase 2Active, not recruiting

Obesity

NCT07575932

Q2 2028

Phase 3Active, not recruiting

Obesity

NCT07400653

Phase 3Recruiting

Obesity

NCT07595549

Clinical

Trials by Indication[1]

Obesity6 trials

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07595549·954 enrolled

A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-08653944 FOLLOWING SINGLE DOSE SUBCUTANEOUS ADMINISTRATION IN OTHERWISE HEALTHY CHINESE ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Not yet recruiting· Pfizer logo

Pfizer·Phase 1·NCT07845513·16 enrolled

A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT07575932·940 enrolled

Show 3 more trials

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT07400653·1,078 enrolled

A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF PF-08653944 WHEN ADMINISTERED ACROSS DIFFERENT INJECTION SITES IN ADULTS WITH OVERWEIGHT OR OBESITY

Completed· Pfizer logo

Pfizer·Phase 1·NCT07400679·48 enrolled

A PHASE 1, OPEN-LABEL, MULTIPLE DOSE STUDY TO INVESTIGATE THE IMPACT OF PF 08653944 ON GASTRIC EMPTYING IN ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT07508241·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for PF-08653944. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-08653944 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-08653944. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Related News